News & Updates
Showing Hepatology articles
Showing
Show Multimedia Only

Bulevirtide safe, effective in HDV-induced cirrhosis with hypertension
27 Nov 2022
A recent study has demonstrated the safety and efficacy of bulevirtide (BLV) monotherapy for 48 weeks in difficult-to-treat patients with hepatitis delta virus (HDV)-related compensated cirrhosis and clinically significant portal hypertension (CSPH).
27 Nov 2022

Which factors raise HCC risk in patients with cured HCV?
24 Nov 2022
byStephen Padilla
Predictors of hepatocellular carcinoma (HCC) differ in patients with virologically cured hepatitis C virus (HCV) infection with and without cirrhosis, according to a study. However, changes in fibrosis-4 (FIB-4) scores over time are associated with HCC risk in both cohorts.
24 Nov 2022






